

Pharmacy Formulary Updates for August 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status August 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO- MA
Symdeko 50-75mg	\$3.65;PA;QL
Nuzyra	\$3.65
Dovato	\$3.65
Inbrija	\$3.65;PA
Bivigam	MB/RX;PA;SP
Fabrazyme	MB/RX;PA;SP
Emcyt	\$3.65;SP
Odomzo	\$3.65;PA;SP
Alyq	\$3.65;PA;QL;SP
Levoleucovorin injection	MB/RX;SP
Veletri	MB/RX;PA;SP
Leuprolide injection	MB/RX;PA
Dexcom G6 Receiver	\$0;PA:QL
Dexcom G6 Transmitter	\$0;PA:QL
Dexcom G6 Sensor	\$0;PA:QL

Key

MB: Medical Benefit

QL: Quantity Limitation

NC: Not covered

SP: Specialty Pharmacy - provided through CVS/specialty

NTM: New-to-market

ST: Step Therapy

MB/RX: Drug can be dispensed through Medical Benefit or Prescription Benefit